📢 POLY-HF: Daily Polypill Boosts Heart Function, QOL, and Cuts Hospitalizations in Underserved Patients With #HFrEF
Read more: https://bit.ly/4hV9byv
#AHA25 #HeartFailure #CardioSky #MedSky
Read more: https://bit.ly/4hV9byv
#AHA25 #HeartFailure #CardioSky #MedSky
November 10, 2025 at 10:35 PM
📢 POLY-HF: Daily Polypill Boosts Heart Function, QOL, and Cuts Hospitalizations in Underserved Patients With #HFrEF
Read more: https://bit.ly/4hV9byv
#AHA25 #HeartFailure #CardioSky #MedSky
Read more: https://bit.ly/4hV9byv
#AHA25 #HeartFailure #CardioSky #MedSky
Of course it has
Today I had to do a peer to peer for sacubitril/valsartan for pt w/HFrEF. They wanted to know what pt had tried and "failed". I said it's ACC/AHA guidelines class I for first-line use
They said: not in "our" guidelines
WTAF
Today I had to do a peer to peer for sacubitril/valsartan for pt w/HFrEF. They wanted to know what pt had tried and "failed". I said it's ACC/AHA guidelines class I for first-line use
They said: not in "our" guidelines
WTAF
October 24, 2025 at 12:41 AM
Of course it has
Today I had to do a peer to peer for sacubitril/valsartan for pt w/HFrEF. They wanted to know what pt had tried and "failed". I said it's ACC/AHA guidelines class I for first-line use
They said: not in "our" guidelines
WTAF
Today I had to do a peer to peer for sacubitril/valsartan for pt w/HFrEF. They wanted to know what pt had tried and "failed". I said it's ACC/AHA guidelines class I for first-line use
They said: not in "our" guidelines
WTAF
Great point!
I think HHF in HFrEF is an exception - events like hospitalization occur so fast that this happens and trials are often stopped early @mikejohansenmd.medsky.social
With flozins-autoimmune disease if we think this is not a direct but a second order effect it should take more time?
I think HHF in HFrEF is an exception - events like hospitalization occur so fast that this happens and trials are often stopped early @mikejohansenmd.medsky.social
With flozins-autoimmune disease if we think this is not a direct but a second order effect it should take more time?
October 16, 2025 at 11:59 AM
Great point!
I think HHF in HFrEF is an exception - events like hospitalization occur so fast that this happens and trials are often stopped early @mikejohansenmd.medsky.social
With flozins-autoimmune disease if we think this is not a direct but a second order effect it should take more time?
I think HHF in HFrEF is an exception - events like hospitalization occur so fast that this happens and trials are often stopped early @mikejohansenmd.medsky.social
With flozins-autoimmune disease if we think this is not a direct but a second order effect it should take more time?
Assessment and plan:
# HFrEF: GDMT
# Cellulitis: GDMT
# Sepsis: E̶G̶D̶T̶
# CKD4: GDMT
# DM2: GDMT
# BPH: saw palmetto
# HLD: 🤪
# DVT ppx: GDMT
# HFrEF: GDMT
# Cellulitis: GDMT
# Sepsis: E̶G̶D̶T̶
# CKD4: GDMT
# DM2: GDMT
# BPH: saw palmetto
# HLD: 🤪
# DVT ppx: GDMT
March 1, 2025 at 6:08 PM
Assessment and plan:
# HFrEF: GDMT
# Cellulitis: GDMT
# Sepsis: E̶G̶D̶T̶
# CKD4: GDMT
# DM2: GDMT
# BPH: saw palmetto
# HLD: 🤪
# DVT ppx: GDMT
# HFrEF: GDMT
# Cellulitis: GDMT
# Sepsis: E̶G̶D̶T̶
# CKD4: GDMT
# DM2: GDMT
# BPH: saw palmetto
# HLD: 🤪
# DVT ppx: GDMT
He talked about it from a general HFrEF point of view, rather than specific pathologies.
But yes- according to the master you can have HFrEF with normal
LV relaxation
But yes- according to the master you can have HFrEF with normal
LV relaxation
January 24, 2025 at 12:40 PM
He talked about it from a general HFrEF point of view, rather than specific pathologies.
But yes- according to the master you can have HFrEF with normal
LV relaxation
But yes- according to the master you can have HFrEF with normal
LV relaxation
【感染症入院でHFリスク高？/JAHA】
米国、多人種コホート、HF診断歴のない14,468例、27年観察：
・25%がHF発症。
・観察開始時感染症関連入院「既往」例では「非既往」例に比べ
HRが2.45 [95%CI：2.19-2.52]。
・リスク増加はHFrEF/pEFとも。
x.gd/BaAWx
米国、多人種コホート、HF診断歴のない14,468例、27年観察：
・25%がHF発症。
・観察開始時感染症関連入院「既往」例では「非既往」例に比べ
HRが2.45 [95%CI：2.19-2.52]。
・リスク増加はHFrEF/pEFとも。
x.gd/BaAWx
American Heart Association Journals
x.gd
January 31, 2025 at 10:54 PM
【感染症入院でHFリスク高？/JAHA】
米国、多人種コホート、HF診断歴のない14,468例、27年観察：
・25%がHF発症。
・観察開始時感染症関連入院「既往」例では「非既往」例に比べ
HRが2.45 [95%CI：2.19-2.52]。
・リスク増加はHFrEF/pEFとも。
x.gd/BaAWx
米国、多人種コホート、HF診断歴のない14,468例、27年観察：
・25%がHF発症。
・観察開始時感染症関連入院「既往」例では「非既往」例に比べ
HRが2.45 [95%CI：2.19-2.52]。
・リスク増加はHFrEF/pEFとも。
x.gd/BaAWx
December 10, 2024 at 6:14 PM
【ケトン体サプリでHF例の心機能改善？小規模RCTメタ解析/ Heart [Sep16]】
HF対象RCT 6報併合 [例数不詳]：
・ケトン体サプリでEFは3.12%の有意増加。
・HFrEFで著明 [4.25%]。
・ただし小規模試験かつ、観察期間不均衡のため、信頼性は「低」。
Heart x.gd/8zFQg
HF対象RCT 6報併合 [例数不詳]：
・ケトン体サプリでEFは3.12%の有意増加。
・HFrEFで著明 [4.25%]。
・ただし小規模試験かつ、観察期間不均衡のため、信頼性は「低」。
Heart x.gd/8zFQg
Effect of ketone supplementation, a low-carbohydrate diet and a ketogenic diet on heart failure measures and outcomes: a systematic review and meta-analysis
Background The impact of ketone supplementation, low carbohydrate diets (LCDs) and ketogenic diets (KDs) on heart failure (HF) outcomes is largely unknown. This systematic review and meta-analysis inv...
x.gd
September 16, 2025 at 10:17 PM
【ケトン体サプリでHF例の心機能改善？小規模RCTメタ解析/ Heart [Sep16]】
HF対象RCT 6報併合 [例数不詳]：
・ケトン体サプリでEFは3.12%の有意増加。
・HFrEFで著明 [4.25%]。
・ただし小規模試験かつ、観察期間不均衡のため、信頼性は「低」。
Heart x.gd/8zFQg
HF対象RCT 6報併合 [例数不詳]：
・ケトン体サプリでEFは3.12%の有意増加。
・HFrEFで著明 [4.25%]。
・ただし小規模試験かつ、観察期間不均衡のため、信頼性は「低」。
Heart x.gd/8zFQg
The PROTECT IV trial will investigate whether routine Impella CP support during high-risk PCI in patients with complex CAD and HFrEF can improve long-term outcomes.
A multicentre, randomised study enrolling 1,252 patients across the US, Canada, and Europe. #cardiosky #impella shorturl.at/161oW
A multicentre, randomised study enrolling 1,252 patients across the US, Canada, and Europe. #cardiosky #impella shorturl.at/161oW
October 1, 2025 at 7:19 AM
The PROTECT IV trial will investigate whether routine Impella CP support during high-risk PCI in patients with complex CAD and HFrEF can improve long-term outcomes.
A multicentre, randomised study enrolling 1,252 patients across the US, Canada, and Europe. #cardiosky #impella shorturl.at/161oW
A multicentre, randomised study enrolling 1,252 patients across the US, Canada, and Europe. #cardiosky #impella shorturl.at/161oW
October 23, 2025 at 11:04 PM
4/
A 1993 study by Benedict et al found that patients with HFpEF had:
☞ Decreased norepinephrine and renin compared to patients with HFrEF
☞ Similar norepinephrine values compared to controls
☞ Very mildly increased renin compared with...
A 1993 study by Benedict et al found that patients with HFpEF had:
☞ Decreased norepinephrine and renin compared to patients with HFrEF
☞ Similar norepinephrine values compared to controls
☞ Very mildly increased renin compared with...
November 16, 2024 at 10:27 PM
4/
A 1993 study by Benedict et al found that patients with HFpEF had:
☞ Decreased norepinephrine and renin compared to patients with HFrEF
☞ Similar norepinephrine values compared to controls
☞ Very mildly increased renin compared with...
A 1993 study by Benedict et al found that patients with HFpEF had:
☞ Decreased norepinephrine and renin compared to patients with HFrEF
☞ Similar norepinephrine values compared to controls
☞ Very mildly increased renin compared with...
Each time you dive into HFrEF, you would find something new👍
www.jacc.org/doi/10.1016/...
www.jacc.org/doi/10.1016/...
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled Trial
www.jacc.org
May 8, 2025 at 5:50 PM
Each time you dive into HFrEF, you would find something new👍
www.jacc.org/doi/10.1016/...
www.jacc.org/doi/10.1016/...
【実臨床外来HF例におけるSSGLT2-i処方率と低処方率集団は？/
JAMA Cardiol [Jul 09]】
米国外来患者レジストリ、HF 759,915例解析：
・SGLT2-i処方率は10.1%。
・EF判明例では、HFrEF 17.9%、mr/pEF 8.9%。
・処方率の少ない集団は「高齢者」「女性」に加え (なぜか)「SBP高
値」例。
x.gd/82Q52
JAMA Cardiol [Jul 09]】
米国外来患者レジストリ、HF 759,915例解析：
・SGLT2-i処方率は10.1%。
・EF判明例では、HFrEF 17.9%、mr/pEF 8.9%。
・処方率の少ない集団は「高齢者」「女性」に加え (なぜか)「SBP高
値」例。
x.gd/82Q52
National Trends of Outpatient HF SGLT2 Inhibitor Therapy
This retrospective cohort study examines use of sodium–glucose cotransporter 2 inhibitor therapy among patients with heart failure treated in US cardiovascular ambulatory care settings.
x.gd
July 9, 2025 at 9:46 PM
【実臨床外来HF例におけるSSGLT2-i処方率と低処方率集団は？/
JAMA Cardiol [Jul 09]】
米国外来患者レジストリ、HF 759,915例解析：
・SGLT2-i処方率は10.1%。
・EF判明例では、HFrEF 17.9%、mr/pEF 8.9%。
・処方率の少ない集団は「高齢者」「女性」に加え (なぜか)「SBP高
値」例。
x.gd/82Q52
JAMA Cardiol [Jul 09]】
米国外来患者レジストリ、HF 759,915例解析：
・SGLT2-i処方率は10.1%。
・EF判明例では、HFrEF 17.9%、mr/pEF 8.9%。
・処方率の少ない集団は「高齢者」「女性」に加え (なぜか)「SBP高
値」例。
x.gd/82Q52
In HFrEF, the reduction in peripheral resistance is counterbalanced by the increase in recruited stroke volume, causing blood pressure to only drop a little.
July 16, 2025 at 8:27 PM
In HFrEF, the reduction in peripheral resistance is counterbalanced by the increase in recruited stroke volume, causing blood pressure to only drop a little.
New online! Benefit of digitoxin therapy for HFrEF #CardioSky
Benefit of digitoxin therapy for HFrEF
Nature Reviews Cardiology, Published online: 11 September 2025; doi:10.1038/s41569-025-01217-zIn the DIGIT-HF trial, treatment with digitoxin in addition to guideline-directed medical therapy reduced the risk of hospitalization for worsening heart failure or all-cause death compared with placebo in patients with heart failure with reduced ejection fraction.
bit.ly
September 11, 2025 at 12:29 PM
New online! Benefit of digitoxin therapy for HFrEF #CardioSky
🔍 New from MESA: Elevated Interleukin-6 + high Coronary Artery Calcium = ↑ risk of heart failure, especially HFrEF, with additive & multiplicative interaction.
ScienceDirect
📈 More proof inflammation + atherosclerosis go hand in hand.
🔗 https://ow.ly/7Mrg50WZW9X
#CardioSky #MedSky
ScienceDirect
📈 More proof inflammation + atherosclerosis go hand in hand.
🔗 https://ow.ly/7Mrg50WZW9X
#CardioSky #MedSky
September 28, 2025 at 4:35 PM
🔍 New from MESA: Elevated Interleukin-6 + high Coronary Artery Calcium = ↑ risk of heart failure, especially HFrEF, with additive & multiplicative interaction.
ScienceDirect
📈 More proof inflammation + atherosclerosis go hand in hand.
🔗 https://ow.ly/7Mrg50WZW9X
#CardioSky #MedSky
ScienceDirect
📈 More proof inflammation + atherosclerosis go hand in hand.
🔗 https://ow.ly/7Mrg50WZW9X
#CardioSky #MedSky
#TECX Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
https://www.stocktitan.net/news/TECX/tectonic-therapeutic-announces-positive-topline-data-from-phase-1b-7r455ayzzzft.html
https://www.stocktitan.net/news/TECX/tectonic-therapeutic-announces-positive-topline-data-from-phase-1b-7r455ayzzzft.html
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
Tectonic Therapeutic (NASDAQ: TECX) announced positive topline Phase 1b Part B results for TX45 in patients with Group 2 pulmonary hypertension associated with HFrEF on October 29, 2025. In 14 enrolled patients a single IV dose produced meaningful hemodynamic improvements including PCWP -29.2%, TPR -29.2%, mPAP -19.3% and CO +17.3%, with echocardiography showing persistent gains at day 29 (LVEF +19.4%, RVFAC +20.3%, TAPSE/SPAP +36.3%). TX45 was well tolerated with no serious or severe adverse events reported. Results support potential expansion into PH‑HFrEF while the company continues the APEX Phase 2 trial with topline 2026 readout expected.
www.stocktitan.net
October 29, 2025 at 8:01 PM
#TECX Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
https://www.stocktitan.net/news/TECX/tectonic-therapeutic-announces-positive-topline-data-from-phase-1b-7r455ayzzzft.html
https://www.stocktitan.net/news/TECX/tectonic-therapeutic-announces-positive-topline-data-from-phase-1b-7r455ayzzzft.html
4/ SGLTis are best for:
🍬 Patients with HFrEF/HFpEF or CKD
🍬 ASCVD or high CV risk
🍬 Patients prioritizing oral route
🍬 Patients w/ “a little bit of everything”
🍬 A1C lowering is not priority
🍬 Patients with HFrEF/HFpEF or CKD
🍬 ASCVD or high CV risk
🍬 Patients prioritizing oral route
🍬 Patients w/ “a little bit of everything”
🍬 A1C lowering is not priority
November 5, 2025 at 12:06 PM
4/ SGLTis are best for:
🍬 Patients with HFrEF/HFpEF or CKD
🍬 ASCVD or high CV risk
🍬 Patients prioritizing oral route
🍬 Patients w/ “a little bit of everything”
🍬 A1C lowering is not priority
🍬 Patients with HFrEF/HFpEF or CKD
🍬 ASCVD or high CV risk
🍬 Patients prioritizing oral route
🍬 Patients w/ “a little bit of everything”
🍬 A1C lowering is not priority
Point-of-care summary of core HFrEF GDMT safety across CKD stages/ ESKD
#Nephpearls #NephSky #Cardiorenal
👉 www.gdmt.org/Contest/
#Nephpearls #NephSky #Cardiorenal
👉 www.gdmt.org/Contest/
November 16, 2024 at 2:42 PM
Point-of-care summary of core HFrEF GDMT safety across CKD stages/ ESKD
#Nephpearls #NephSky #Cardiorenal
👉 www.gdmt.org/Contest/
#Nephpearls #NephSky #Cardiorenal
👉 www.gdmt.org/Contest/
Put a patient with HFrEF and nephrotic syndrome with T2DM on the “nephro bomb” after being consulted for failure to diurese on lasix drip at 10 mg/hr. Added acetazolemide 500mg bid and metolazone 5 mg daily.
Went from 2.5 L to 15 L/24 hr urine!! #NephSky
Went from 2.5 L to 15 L/24 hr urine!! #NephSky
a man with a beard is smiling and wearing a hat
ALT: a man with a beard is smiling and wearing a hat
media.tenor.com
December 6, 2024 at 1:38 PM
Put a patient with HFrEF and nephrotic syndrome with T2DM on the “nephro bomb” after being consulted for failure to diurese on lasix drip at 10 mg/hr. Added acetazolemide 500mg bid and metolazone 5 mg daily.
Went from 2.5 L to 15 L/24 hr urine!! #NephSky
Went from 2.5 L to 15 L/24 hr urine!! #NephSky
Yes... the problem is that people want the path of least resistance: it blows to see people without HFrEF and kidney disease being on 100+ mg of this worthless for HTN POS instead of literary anything else in the planet
December 7, 2024 at 4:15 PM
Yes... the problem is that people want the path of least resistance: it blows to see people without HFrEF and kidney disease being on 100+ mg of this worthless for HTN POS instead of literary anything else in the planet
all these lib nurses talking about how “trump has chf and is about to die” are really showing their asses. like 1 chf isn’t a diagnosis they use anymore, it’s either heart failure with preserved or reduced ejection fraction(HFpEF/HFrEF) and 2 you know damn well it’s a totally manageable condition
July 19, 2025 at 5:04 AM
all these lib nurses talking about how “trump has chf and is about to die” are really showing their asses. like 1 chf isn’t a diagnosis they use anymore, it’s either heart failure with preserved or reduced ejection fraction(HFpEF/HFrEF) and 2 you know damn well it’s a totally manageable condition
Yes she has bad HFrEF and is on pacemaker. Baseline Na according to records is around 129-132.
November 17, 2024 at 7:38 AM
Yes she has bad HFrEF and is on pacemaker. Baseline Na according to records is around 129-132.
In a European cohort, lifetime risk of developing HFrEF was greater in men, while women were at greater risk of developing HFpEF.
8 modifiable RFs substantially accounted for developing HF.
#CardioSky
academic.oup.com/eurheartj/ad...
@anastasiasmihaili.bsky.social @vietheartpa.bsky.social
8 modifiable RFs substantially accounted for developing HF.
#CardioSky
academic.oup.com/eurheartj/ad...
@anastasiasmihaili.bsky.social @vietheartpa.bsky.social
February 5, 2025 at 1:30 PM
In a European cohort, lifetime risk of developing HFrEF was greater in men, while women were at greater risk of developing HFpEF.
8 modifiable RFs substantially accounted for developing HF.
#CardioSky
academic.oup.com/eurheartj/ad...
@anastasiasmihaili.bsky.social @vietheartpa.bsky.social
8 modifiable RFs substantially accounted for developing HF.
#CardioSky
academic.oup.com/eurheartj/ad...
@anastasiasmihaili.bsky.social @vietheartpa.bsky.social
A recent TCTMD feature story delves into the underuse of GDMT for patients with HFrEF. As @shelleyzieroth.bsky.social explains, “these are lifesaving, disease-modifying therapies, and our patients need rapid access to them.” Full story here: www.tctmd.com/news/gdmt-up... @toddneale.bsky.social
November 22, 2024 at 10:03 PM
A recent TCTMD feature story delves into the underuse of GDMT for patients with HFrEF. As @shelleyzieroth.bsky.social explains, “these are lifesaving, disease-modifying therapies, and our patients need rapid access to them.” Full story here: www.tctmd.com/news/gdmt-up... @toddneale.bsky.social